Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.
J Infect Dis
; 226(5): 881-890, 2022 09 13.
Article
em En
| MEDLINE
| ID: mdl-34931674
ABSTRACT
BACKGROUND:
Whether serum hepatitis B virus (HBV) RNA associates with hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients has not been fully elucidated.METHODS:
We enrolled 2974 patients receiving nucleos(t)ide analogues (NAs) from a prospective, observational CHB cohort to investigate the effect of serum HBV RNA, measured at study entry (baseline), on HCC development, using Cox regression analyses.RESULTS:
During median follow-up of 4.4 years, 90 patients developed HCC. Patients with detectable baseline HBV RNA (nâ =â 2072) exhibited significantly higher HCC risk than those with undetectable level (5-year HCC incidence estimated by Kaplan-Meiermethod:
4.1% versus 1.8%, Pâ =â .009; adjusted hazard ratio [aHR]â =â 2.21, Pâ =â .005). HBV RNA levels of 609-99 999 andâ ≥100 000 copies/mL were associated with incrementally increasing HCC risk (aHRâ =â 2.15 and 3.05, respectively; P for trendâ =â .003), compared to undetectable level (<609 copies/mL). Moreover, patients with single-detectable either HBV DNA or RNA and double-detectable DNA and RNA had 1.57- and 4.02-fold higher HCC risk, respectively, than those with double-undetectable DNA and RNA (P for trendâ =â .001).CONCLUSIONS:
High-level HBV RNA is associated with increased HCC risk in NAs-treated patients. Achieving undetectable HBV RNA may contribute to better clinical outcomes, indicating it could be a valuable endpoint of anti-HBV treatment.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Hepatocelular
/
Hepatite B Crônica
/
Neoplasias Hepáticas
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
En
Revista:
J Infect Dis
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
China